(468) Low risk of aberrant drug-related behavior observed during a 12-month open-label study in patients taking an extended-release hydrocodone tablet, formulated with OraGuard™ technology, for chronic noncancer pain

✍ Scribed by Hale, M.; Zimmerman, T.; Ma, Y.; Malamut, R.

• Book ID: 122131790
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 96 KB
• Volume: 15
• Category: Article
• ISSN: 1528-8447
• DOI: 10.1016/j.jpain.2014.01.379